TWD
TNGX icon

True Wealth Design’s Tango Therapeutics TNGX Stock Holding History

True Wealth Design’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-16
Closed -$22 – 2823
2025
Q1 		$22 Buy
+16
New +$39 ﹤0.01% 2576

Other funds holding TNGX

TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return

True Wealth Design's TNGX Position: Q2 2025 in Review

True Wealth Design sold out of Tango Therapeutics (TNGX) in Q2 2025, closing a stake of 16 shares — an estimated $22 sold.

True Wealth Design first reported a position in TNGX in Q1 2025 and held it in 1 quarter. The position peaked at $22 in Q1 2025. 115 funds tracked by Wall St. Rank hold TNGX as of Q2 2025.

  • True Wealth Design reported no remaining Tango Therapeutics position as of Q2 2025 after selling out during the quarter.
  • True Wealth Design sold 16 Tango Therapeutics shares in Q2 2025, an estimated $22.
  • True Wealth Design first reported a position in Tango Therapeutics in Q1 2025 and held it in 1 quarter.
  • True Wealth Design's Tango Therapeutics position peaked at $22 in Q1 2025.
  • 115 funds tracked by Wall St. Rank held Tango Therapeutics as of Q2 2025.

Based on True Wealth Design's 13F filing for Q2 2025, filed 6 Aug 2025.